# 2026-16715: FDA Seeks Feedback on Updating IND Application Information Requirements

2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-17, effective Submit written comments (including recommendations) on the collection of information by September 16, 2026.; PRIA reads it as touching household money (as of 2026-08-24).

- Canonical: https://policyrisk.com/federal-register/2026-16715
- As of: 2026-08-24
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16715
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53262
- Published: 2026-08-17
- Effective: Submit written comments (including recommendations) on the collection of information by September 16, 2026.
- Comments close: 2026-09-16
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-08-24

## In one line

FDA Seeks Feedback on Updating IND Application Information Requirements

## Summary

The FDA is updating how it collects info for Investigational New Drug (IND) applications, which doctors and researchers use to test new or unapproved drugs. They want your feedback by September 16, 2026, to make sure the process is clear and efficient. This update affects anyone running clinical drug studies and aims to keep things smooth without adding extra costs or delays.

## Abstract

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

## Effects PRIA read

- Form FDA 1571 Adds RWE/RWD Fields: cost, low. If you file an IND using Form FDA 1571, the form was updated to include new real‑world evidence/real‑world data (RWE/RWD) tracking fields per the PDUFA VII commitment. FDA says these new fields will capture submissions that include RWE/RWD so the Agency can track and report on related performance.
- Electronic IND Submission & Web Interface: mixed, medium. Information for INDs must be submitted electronically and FDA offers a new web-based interface (mobile or desktop) to help complete and electronically submit Form FDA 1571 and associated files. Individuals may request printed forms by email, but fees may apply for printed copies.
- Large Annual Reporting & Recordkeeping Burden: cost, high. FDA estimates very large annual burden hours from IND reporting and recordkeeping: for human drugs, 23,016,423 reporting hours and 2,832,742 recordkeeping hours annually; for biologics, 6,694,050 reporting hours and 127,220 recordkeeping hours annually. These totals reflect the cumulative time resp…
- Right to Try Annual Report Due March 31: cost, low. Sponsors and manufacturers who provide an "eligible investigational drug" under the Right to Try Act must submit an annual report using Form FDA 5023 by March 31 each year covering the preceding calendar year. FDA lists this requirement under 21 CFR 300.200.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16715 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/17/2026-16715/agency-information-collection-activities-proposed-collection-comment-request-investigational-new)
- [2026-16715 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-17/pdf/2026-16715.pdf)

## Related
- [Previous: 2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-16714)
- [Next: 2026-16716, Agency Information Collection Activities; Announcement of Office of Management…](https://policyrisk.com/federal-register/2026-16716)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16715 (as of 2026-08-24).
